Author

John Hardin

University of Colorado Anschutz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Adam David DurbiniD· 1 shared Alexander LaVeck· 1 shared Andrew Lee HongiD· 1 shared Annika L. GustafsoniD· 1 shared Anoop Murthy KavirayaniiD· 1 shared Arthur R. WoliniD· 1 shared Berkley E. GryderiD· 1 shared Brian J. AbrahamiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam David DurbinORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Annika L. Gustafson, Stephanie Nance, Berkley E. Gryder, Noha A.M. Shendy, Lars Wick, Grace B. McKay-Corkum, K. Elaine Ritter, Stephen Connor Purdy, Arthur R. Wolin, Sheera R. Rosenbaum, Sabateeshan Mathavarajah, Nickerson A. Demelfi, Yueyang Wang, Yang Zhang, Mark W. Zimmerman, , Adam David Durbin

The paper identifies a core regulatory circuit in rhabdomyosarcoma and shows that targeting two co-activators synergistically inhibits tumor growth.

bioRxiv · Sep 3, 2026 · PreprintCancer Biology